Renovaro Inc (RENB)
0.97
+0.05
(+5.75%)
USD |
NASDAQ |
May 17, 16:00
0.97
0.00 (0.00%)
After-Hours: 20:00
Renovaro Cash from Financing (Quarterly): 2.641M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.641M |
| December 31, 2023 | 2.847M |
| September 30, 2023 | 2.563M |
| June 30, 2023 | 1.248M |
| March 31, 2023 | 2.109M |
| December 31, 2022 | -0.30M |
| September 30, 2022 | 1.458M |
| June 30, 2022 | 1.070M |
| March 31, 2022 | 0.2295M |
| December 31, 2021 | 2.951M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 29.20M |
| March 31, 2021 | 3.439M |
| December 31, 2020 | -0.0404M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 6.20M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 1.00M |
| June 30, 2019 | 4.32M |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 1.70M |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 11.90M |
| Date | Value |
|---|---|
| December 31, 2017 | 4.817M |
| September 30, 2017 | -0.0045M |
| June 30, 2017 | 5.093M |
| March 31, 2017 | 0.0528M |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.3609M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 5.281M |
| September 30, 2014 | 0.5302M |
| June 30, 2014 | -0.0072M |
| March 31, 2014 | 0.866M |
| December 31, 2013 | 0.0037M |
| September 30, 2013 | 0.0095M |
| June 30, 2013 | 0.0005M |
| March 31, 2013 | 0.009M |
| December 31, 2012 | 0.0075M |
| September 30, 2012 | 0.009M |
| June 30, 2012 | 0.011M |
| March 31, 2012 | 0.005M |
| December 31, 2011 | 0.0035M |
| September 30, 2011 | 0.025M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.30M
Minimum
Dec 2022
29.20M
Maximum
Jun 2021
3.047M
Average
1.353M
Median
Cash from Financing (Quarterly) Benchmarks
| DIH Holding US Inc | -- |
| AIM ImmunoTech Inc | 0.147M |
| Perspective Therapeutics Inc | 166.33M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.634M |
| Cash from Investing (Quarterly) | -0.0916M |
| Free Cash Flow | -10.87M |
| Free Cash Flow Per Share (Quarterly) | -0.0246 |
| Free Cash Flow Yield | -15.13% |